{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:17:19Z","timestamp":1720534639498},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":4581,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1093\/annonc\/mdm241","type":"journal-article","created":{"date-parts":[[2007,6,25]],"date-time":"2007-06-25T12:38:59Z","timestamp":1182775139000},"page":"vi128-vi132","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S6","title":["Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study"],"prefix":"10.1016","volume":"18","author":[{"given":"G.","family":"Rosati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bilancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dinota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Manzione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm241_bb0005","first-page":"179","article-title":"NCCN practice guidelines for upper gastrointestinal carcinomas","volume":"12","year":"1998","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm241_bb0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdh007","article-title":"Phase II study of irinotecan and 5-fluorouracil\/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma","volume":"15","author":"Assersohn","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s002800050989","article-title":"The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review","volume":"44","author":"Wang","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdm241_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02993858","article-title":"Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293","volume":"13","author":"Einzig","year":"1996","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bjc.1994.310","article-title":"Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group","volume":"70","author":"Sulkes","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm241_bb0030","first-page":"4219","article-title":"Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.)","volume":"23","author":"Giuliani","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdm241_bb0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000069313","article-title":"A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Clinical Study Group of Capecitabine","volume":"64","author":"Koizumi","year":"2003","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm241_bb0040","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol\/Taxotere in human xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm241_bb0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1054\/bjoc.2000.1160","article-title":"A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours","volume":"83","author":"Pronk","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm241_bb0050","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.coc.0000143877.53314.9c","article-title":"Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer","volume":"28","author":"Chun","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0060","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/sj.bjc.6601724","article-title":"A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer","volume":"90","author":"Park","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm241_bb0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl005","article-title":"Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group","volume":"17","author":"Giordano","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000086773","article-title":"Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer","volume":"68","author":"Kim","year":"2005","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm241_bb0075","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdl168","article-title":"Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study","volume":"17","author":"Orditura","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm241_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm241_bb0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trials of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"10.1093\/annonc\/mdm241_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdm241_bb0095","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdl134","article-title":"Detailed analysis of a randomised phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?","volume":"17","author":"Leonard","year":"2006","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419474516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419474516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/suppl_6\/vi128\/6673357\/mdm241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:49:36Z","timestamp":1582199376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419474516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":19,"alternative-id":["S0923753419474516"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm241","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}